Used in targeted cancer therapy, particularly in triple-negative breast cancer. Binds specifically to P-cadherin, a protein overexpressed in certain tumor cells, enabling selective delivery of cytotoxic agents. This antibody is part of an antibody-drug conjugate (ADC) platform, where it acts as the targeting component linked to a potent chemotherapy payload. Helps minimize damage to healthy tissues by directing treatment to cancer cells expressing P-cadherin. Currently investigated in clinical trials to evaluate efficacy and safety in solid tumors.